We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
An7.0
Aniracetam Research
Mostly mechanism / observationalHigh safety
9 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Aniracetam studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2007–2020 with a typical study size of 88 participants.
Based on 9 studies · 1 meta-analysis · 5 RCTs · 45,513 total participants
3Mild cognitive impairmentRCTCited 6×n=166 · medium study2007
Shenwu gelatin capsule has certain effects on mild cognitive impairment.
Zhong J et al. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
Shenwu gelatin capsule has certain effects on mild cognitive impairment.
Further research warranted to confirm findings
4Cognitive behavior ability in vascular dementiaRCTCited 9×n=88 · small study2014
The scalp acupuncture combined with auricular point sticking could improve the clinical symptoms and cognitive behavior ability in patients with vascular dementia, which has superior total efficacy to body acupuncture and western medication aniracetam tablets.
Li SK et al. · Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2014)
Huge benefit
← WorseNo effectBetter →
The total effective rate was 90.334 (28/31) in the combined therapy group, which was superior to 85.734 (24/28) in the body acupuncture group and 79.3% (23/29) in the western medication group (both P < 0.05).
The scalp acupuncture combined with auricular point sticking could improve the clinical symptoms and cognitive behavior ability in patients with vascular dementia, which has superior total efficacy to body acupuncture and western medication aniracetam tablets.
Further research warranted to confirm findings
5Clinical memory scale scoresRCTCited 12×n=45 · small study2008
Huannao Yicong capsule has better therapeutic effect than aniracetam capsule in treating senile mild cognitive impairment.
Li H et al. · Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine (2008)
Likely real
Other index scores of clinical memory scale and traditional Chinese medicine syndrome in patients of Huannao Yicong capsule-treated group were significantly improved as compared with those of the aniracetam-treated group (P<0.05, P<0.01).
Huannao Yicong capsule could significantly increase the activity of serum SOD and decrease the content of AchE, IL-1alpha and IL-6 (P<0.01, P<0.05), better than aniracetam.
Furthermore, Huannao Yicong capsule could significantly improve the blood lipid, such as the level of TG, LDL-C, HDL-C, ApoA-1 and ApoB-100 (P<0.01, P<0.05), and better than aniracetam (P<0.01, P<0.05).
6Mild cognitive impairment symptomsRCTCited 7×n=64 · small study2010
For treatment of MCI, HWD shows effects in improving patients' symptoms, cognition capacity and elevating serum Ach content better than that of Aniracetam; and with effects for raising SOD activity and reducing MDA level similar to those of Aniracetam.
Guo RZ et al. · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (2010)
For treatment of MCI, HWD shows effects in improving patients' symptoms, cognition capacity and elevating serum Ach content better than that of Aniracetam; and with effects for raising SOD activity and reducing MDA level similar to those of Aniracetam.
Further research warranted to confirm findings
7Bioequivalence of aniracetam formulationsRCTn=20 · very small study2011
Therefore, the aniracetam test formulation can be regarded as bioequivalent to the aniracetam reference formulation.
Tian Y et al. · Arzneimittel-Forschung (2011)
The 90% confidence limits calculated for AUC and Cmax of aniracetam were within the standard bioequivalence range (80%-125% for AUC and Cmax).
AUC(0-2.5) values were 4.53 +/- 6.62 and 4.76 +/- 6.65 ng h/mL, the areas under the plasma concentration-time curve (AUC(0-infinity) were 4.62 +/- 6.66 and 4.85 +/- 6.71 ng h/mL for the test and reference formulation, respectively.
No statistical differences were observed for Cmax, and AUC(0-infinity) for aniracetam.
8Cognitive impairmentObservationalCited 16×n=276 · medium study2012
Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.
Koliaki CC et al. · CNS neuroscience & therapeutics (2012)
In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months.
Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.
It preserved all neuropsychological parameters for at least 12 months, and seemed to exert a favorable effect on emotional stability of demented patients.